Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).Materials and Methods. A Mar...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2020-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696905066446848 |
|---|---|
| author | S. V. Nedogoda M. Yu. Frolov A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_facet | S. V. Nedogoda M. Yu. Frolov A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_sort | S. V. Nedogoda |
| collection | DOAJ |
| description | Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).Materials and Methods. A Markov model was used for the estimation of direct medical costs associated with different medications. Costminimization and budget impact analyses were performed.Results. The drug costs for T+O were the lowest among all compared treatment strategies. The cost savings in favor of T+O were 24.82% [15.86–29.95%]. The application of T+O strategy in 4,101 target patients led to a decrease in the total direct medical costs under the state programs of guarantees of free medical care by 13.13% in 3 years, which will make T+O therapy available to 643 more patients in the first year and 1,624 patients in three years.Conclusion. A fixed combination T+O is a preferred efficient option for maintenance triple treatment for patients with COPD in comparison with other drugs from VEDL, because it is associated with lower total costs and equal efficacy. |
| format | Article |
| id | doaj-art-8fb52a2ddbde4e21bc5cee65b83d1275 |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2020-08-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-8fb52a2ddbde4e21bc5cee65b83d12752025-08-20T03:19:20ZrusIRBIS LLCФармакоэкономика2070-49092070-49332020-08-0113210111110.17749/2070-4909/farmakoekonomika.2020.045296Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian FederationS. V. Nedogoda0M. Yu. Frolov1A. S. Salasyuk2I. N. Barykina3V. O. Smirnova4Volgograd State Medical University of the Ministry of Health of the Russian FederationVolgograd State Medical University of the Ministry of Health of the Russian Federation; Volgograd medical scientific centerVolgograd State Medical University of the Ministry of Health of the Russian FederationVolgograd State Medical University of the Ministry of Health of the Russian FederationVolgograd State Medical University of the Ministry of Health of the Russian FederationAim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).Materials and Methods. A Markov model was used for the estimation of direct medical costs associated with different medications. Costminimization and budget impact analyses were performed.Results. The drug costs for T+O were the lowest among all compared treatment strategies. The cost savings in favor of T+O were 24.82% [15.86–29.95%]. The application of T+O strategy in 4,101 target patients led to a decrease in the total direct medical costs under the state programs of guarantees of free medical care by 13.13% in 3 years, which will make T+O therapy available to 643 more patients in the first year and 1,624 patients in three years.Conclusion. A fixed combination T+O is a preferred efficient option for maintenance triple treatment for patients with COPD in comparison with other drugs from VEDL, because it is associated with lower total costs and equal efficacy.https://www.pharmacoeconomics.ru/jour/article/view/383chronic obstructive pulmonary diseasemaintenance therapybronchodilatorstiotropiumolodaterolfixed combinationcost-minimization analysisbudget impact analysiscost-effectiveness analysispharmacoeconomic modeling |
| spellingShingle | S. V. Nedogoda M. Yu. Frolov A. S. Salasyuk I. N. Barykina V. O. Smirnova Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation Фармакоэкономика chronic obstructive pulmonary disease maintenance therapy bronchodilators tiotropium olodaterol fixed combination cost-minimization analysis budget impact analysis cost-effectiveness analysis pharmacoeconomic modeling |
| title | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation |
| title_full | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation |
| title_fullStr | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation |
| title_full_unstemmed | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation |
| title_short | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation |
| title_sort | pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with copd in the russian federation |
| topic | chronic obstructive pulmonary disease maintenance therapy bronchodilators tiotropium olodaterol fixed combination cost-minimization analysis budget impact analysis cost-effectiveness analysis pharmacoeconomic modeling |
| url | https://www.pharmacoeconomics.ru/jour/article/view/383 |
| work_keys_str_mv | AT svnedogoda pharmacoeconomicanalysisoftiotropiumbromideandolodaterolfixedcombinationasmaintenancetherapyforpatientswithcopdintherussianfederation AT myufrolov pharmacoeconomicanalysisoftiotropiumbromideandolodaterolfixedcombinationasmaintenancetherapyforpatientswithcopdintherussianfederation AT assalasyuk pharmacoeconomicanalysisoftiotropiumbromideandolodaterolfixedcombinationasmaintenancetherapyforpatientswithcopdintherussianfederation AT inbarykina pharmacoeconomicanalysisoftiotropiumbromideandolodaterolfixedcombinationasmaintenancetherapyforpatientswithcopdintherussianfederation AT vosmirnova pharmacoeconomicanalysisoftiotropiumbromideandolodaterolfixedcombinationasmaintenancetherapyforpatientswithcopdintherussianfederation |